Why the study?
Does intra-arterial therapy increase the risk of symptomatic intracerebral hemorrhage in acute ischemic stroke patients with an INR > 1.7 compared to those with an INR ≤ 1.7?
Does intra-arterial therapy increase the risk of symptomatic intracerebral hemorrhage in acute ischemic stroke patients with an INR > 1.7 compared to those with an INR ≤ 1.7?
Intra-arterial therapy appears safe for acute ischemic stroke patients on oral anticoagulants with an INR > 1.7, without significantly increasing the risk of symptomatic intracerebral hemorrhage compared to patients with an INR ≤ 1.7.
IAT may not raise sICH risk at INR >1.7; leaves open need for randomized confirmation before practice change.
BACKGROUND AND PURPOSE: An elevated international normalized ratio (INR) of >1.7 is a contraindication for the use of intravenous thrombolytics in acute ischaemic stroke. Local intra-arterial therapy (IAT) is considered a safe alternative. The safety and outcome of IAT were investigated in patients with acute ischaemic stroke using oral anticoagulants (OACs). METHODS: Data were obtained from a large national Dutch database on IAT in acute stroke patients. Patients were categorized according to the INR: >1.7 and ≤1.7. Primary outcome was symptomatic intracerebral hemorrhage (sICH), defined as deterioration in the National Institutes of Health Stroke Scale score of ≥4 and ICH on brain imaging. Secondary outcomes were clinical outcome at discharge and 3 months. Occurrence of outcomes was compared with risk ratios and corresponding 95% confidence intervals. Further, a systematic review and meta-analysis on sICH risk in acute stroke patients on OACs treated with IAT was performed. RESULTS: Four hundred and fifty-six patients were included. Eighteen patients had an INR > 1.7 with a median INR of 2.4 (range 1.8-4.1). One patient (6%) in the INR > 1.7 group developed a sICH compared with 53 patients (12%) in the INR ≤ 1.7 group (risk ratio 0.49, 95% confidence interval 0.07-3.13). Clinical outcomes did not differ between the two groups. Our meta-analysis showed a first week sICH risk of 8.1% (95% confidence interval 3.9%-17.1%) in stroke patients with elevated INR treated with IAT. CONCLUSION: The use of OACs, leading to an INR > 1.7, did not seem to increase the risk of an sICH in patients with an acute stroke treated with IAT.
No takes yet. Share an insight, caveat, or question.
Rozeman et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: